MX9703077A - Uso de acetonitrila [r-(z)]-alfa-(metoximino)-alfa-(1-azabiclico [2.2.2.] oct-3-ilo) para reducir formacion de amiloide beta a4 en enfermedad de alzheimer. - Google Patents

Uso de acetonitrila [r-(z)]-alfa-(metoximino)-alfa-(1-azabiclico [2.2.2.] oct-3-ilo) para reducir formacion de amiloide beta a4 en enfermedad de alzheimer.

Info

Publication number
MX9703077A
MX9703077A MX9703077A MX9703077A MX9703077A MX 9703077 A MX9703077 A MX 9703077A MX 9703077 A MX9703077 A MX 9703077A MX 9703077 A MX9703077 A MX 9703077A MX 9703077 A MX9703077 A MX 9703077A
Authority
MX
Mexico
Prior art keywords
alpha
alzheimer
disease
acetonitrile
methoxyimino
Prior art date
Application number
MX9703077A
Other languages
English (en)
Other versions
MXPA97003077A (es
Inventor
Roger Edward Markwell
Julie Hawkins
Carol Wendy Gray
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9703077A publication Critical patent/MX9703077A/es
Publication of MXPA97003077A publication Critical patent/MXPA97003077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un método para aumentar el procesamiento de la proteína precursora amiloide a lo largo de un camino no amiloidogénico en pacientes que sufren de, o que están en peligro de desarrollar, enfermedad de Alzheimer y un método para el tratamiento o profilaxis de la enfermedad de Alzheimer reduciendo la produccion de betaAA4 en pacientes que sufre de, o que están en peligro de desarrollar, enfermedad de Alzheimer que comprende administrar al paciente una cantidad efectiva no toxica de un compuesto de acetonitrila, el uso del compuesto en la preparacion de un medicamento para usarse en el método y una composicion para usarse en el método.
MXPA/A/1997/003077A 1994-10-25 1995-10-17 Uso de acetonitrila [r-(z)]-alfa-(metoximino)-alfa-(1-azabiciclo [2.2.2.]oct-3-ilo) para reducir formacion de amiloide beta a4 en la enfermedad de alzheimer MXPA97003077A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421427.3 1994-10-25
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
PCT/EP1995/004082 WO1996012486A1 (en) 1994-10-25 1995-10-17 Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Publications (2)

Publication Number Publication Date
MX9703077A true MX9703077A (es) 1997-07-31
MXPA97003077A MXPA97003077A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
HK1002057A1 (en) 1998-07-31
AU3843195A (en) 1996-05-15
HUT77007A (hu) 1998-03-02
NZ295155A (en) 2000-07-28
GB9421472D0 (en) 1994-12-07
CN1085529C (zh) 2002-05-29
ES2173977T3 (es) 2002-11-01
ZA958946B (en) 1996-08-20
NO971899L (no) 1997-04-24
DE69526102T2 (de) 2002-10-31
NO971899D0 (no) 1997-04-24
BG101500A (en) 1998-01-30
BR9509433A (pt) 1997-09-16
ATE214926T1 (de) 2002-04-15
KR100393365B1 (ko) 2003-12-18
DK0786998T3 (da) 2002-07-15
EP0786998A1 (en) 1997-08-06
CZ125197A3 (en) 1997-07-16
EP0786998B1 (en) 2002-03-27
CN1170365A (zh) 1998-01-14
KR970706816A (ko) 1997-12-01
SK50497A3 (en) 1997-09-10
CZ287370B6 (en) 2000-11-15
NO312055B1 (no) 2002-03-11
WO1996012486A1 (en) 1996-05-02
AU698695B2 (en) 1998-11-05
DE69526102D1 (de) 2002-05-02
JPH10509697A (ja) 1998-09-22
PT786998E (pt) 2002-09-30
US5891887A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
EP0377520A3 (en) Use of nicotine for the manufacture of a kit for the treatment of conditions susceptible to said treatment
ZA928213B (en) Improvements in and relating to the treatment of motor neurone disease.
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
UA29464C2 (uk) Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
HK1002057A1 (en) Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease
HUP9904401A2 (hu) [R-(Z)]-alfa-(Metoxi-imino)-alfa-(1-aza-biciklo[2.2.2]okt-3-il)-acetonitril-monohidroklorid hatóanyag-tartalmú szabályozott kibocsátású dózisforma
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
HUP0103149A2 (hu) Gyógyszerkészítmény Alzheimer-kór kezelésére
ZA933567B (en) Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease
EP0228239A3 (en) Preparation of a medicament for arthritis and rheumatism
Gouin et al. Treatment of bronchopulmonary infections with dibekacin.
IL71712A0 (en) Pharmaceutical compositions for the treatment and prophylaxis of infections and obstructive respiratory tract diseases and their preparation
SOHN et al. Sulfadimethoxine Use in Chronic Urinary Drainage
IL153003A0 (en) Medicaments for treating colics
SI0786998T1 (en) Use of r-(z))-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2) oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease